You are here

Alpha Cognition Inc.

Alpha Cognition Inc.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
ACOG
CSE Index: 
Currency: 

Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS.  ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.  

You are here

Alpha Cognition Inc. (ACOG)

SEDAR Information

Company Info

Address
20073 Fiddler’s Green
Frisco, TX 75036
United States
Phone
(858) 344-4375
Email
mmcfadden@alphacognition.com
Website
https://www.alphacognition.com
Listing date
Monday, May 1, 2023
Transfer Agent
Computershare Investor Services Inc.

Capitalization

Issued & Outstanding: 
149925536
Reserved for Issuance: 
96869690

Company Officers

Michael McFadden, Chief Executive Officer
Don Kalkofen, Chief Financial Officer
Ken Cawkell, Corporate Secretary
Lauren D'Angelo, Chief Operating Officer
Len Mertz, Chairman

Bulletins

03/10/2023

2023-1003 - Expiry - Alpha Cognition Inc. - 1OCT2023 Warrants (ACOG.WT)

le 3 octobre/October 2023

Alpha Cognition Inc. - 1OCT2023 Warrants listed on May 1, 2023 expired on October 1, 2023.

Trading is currently halted.

The warrants will be delisted at market close October 3, 2023.

________________________

Alpha Cognition Inc. - 1OCT2023 Les bons de souscription cotés le 1er mai 2023 ont expiré le 1er octobre 2023.